Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
5.3834 EUR
4.03 B EUR
115.66 M EUR
376.90 M
About Roivant Sciences Ltd.
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Roivant Sciences Ltd. stocks are traded under the ticker A3C4MS.
A3C4MS stock has fallen by −0.96% compared to the previous week, the month change is a −0.96% fall, over the last year Roivant Sciences Ltd. has showed a −0.96% decrease.
We've gathered analysts' opinions on Roivant Sciences Ltd. future price: according to them, A3C4MS price has a max estimate of 17.33 EUR and a min estimate of 12.51 EUR. Watch A3C4MS chart and read a more detailed Roivant Sciences Ltd. stock forecast: see what analysts think of Roivant Sciences Ltd. and suggest that you do with its stocks.
A3C4MS stock is 0.97% volatile and has beta coefficient of 0.83. Track Roivant Sciences Ltd. stock price on the chart and check out the list of the most volatile stocks — is Roivant Sciences Ltd. there?
Yes, you can track Roivant Sciences Ltd. financials in yearly and quarterly reports right on TradingView.
Roivant Sciences Ltd. is going to release the next earnings report on Feb 17, 2025. Keep track of upcoming events with our Earnings Calendar.
A3C4MS earnings for the last quarter are −0.26 EUR per share, whereas the estimation was −0.22 EUR resulting in a −15.50% surprise. The estimated earnings for the next quarter are −0.24 EUR per share. See more details about Roivant Sciences Ltd. earnings.
Roivant Sciences Ltd. revenue for the last quarter amounts to 4.02 M EUR, despite the estimated figure of 41.24 M EUR. In the next quarter, revenue is expected to reach 4.83 M EUR.
A3C4MS net income for the last quarter is −206.74 M EUR, while the quarter before that showed 88.97 M EUR of net income which accounts for −332.37% change. Track more Roivant Sciences Ltd. financial stats to get the full picture.
No, A3C4MS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 16, 2025, the company has 908.00 employees. See our rating of the largest employees — is Roivant Sciences Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Roivant Sciences Ltd. EBITDA is −1.00 B EUR, and current EBITDA margin is −847.72%. See more stats in Roivant Sciences Ltd. financial statements.
Like other stocks, A3C4MS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Roivant Sciences Ltd. stock right from TradingView charts — choose your broker and connect to your account.